Showing results (131-140 of 285) with videos related to

Sort By:
Pageof 29
Journal of Oncology Practice|October 19, 2012
Consent timing and experience: modifiable factors that may influence interest in clinical researchDavid E Gerber, Drew W Rasco, Celette Sugg Skinner, et al.
Psycho-Oncology|October 15, 2013
Stigma among patients with lung cancer: a patient-reported measurement modelHeidi A Hamann, Jamie S Ostroff, Emily G Marks, et al.
Cancer Medicine|April 23, 2020
Closing the gap: Contribution of surgical best practices to outcome differences between high- and low-volume centers for lung cancer resectionMitchell S von Itzstein, Rong Lu, Kemp H Kernstine, et al.
Lung Cancer (Amsterdam, Netherlands)|September 20, 2014
Bavituximab plus paclitaxel and carboplatin for the treatment of advanced non-small-cell lung cancerRaghunadharao Digumarti, P P Bapsy, Attili V Suresh, et al.
Patient Education and Counseling|June 27, 2019
Patient and provider perspectives on delivery of oral cancer therapiesCaitlin C Murphy, Simon J Craddock Lee, David E Gerber, et al.
International Journal of Radiation Oncology, Biology, Physics|May 4, 2018
Patterns of Failure in Patients With Double Hit or Double Expressor Lymphomas: Implications for Radiation TherapyVasu Tumati, Lakshya Trivedi, Hsiao-Ching Li, et al.
Cancer Medicine|February 24, 2026
Hospitalist Care for Unplanned Oncology Admissions: A Mixed-Method Analysis of Oncology and General Hospitalist Outcomes and ProcessesMegan A Mullins, Sanah Ladhani, Abril Carrillo, et al.
JCO Clinical Cancer Informatics|February 26, 2019
Mobile Device Applications for Electronic Patient Portals in OncologyKelvin K Pho, Rong Lu, Samantha Gates, et al.
The Oncologist|January 11, 2024
Incidence, Correlates, and Prognostic Significance of Mixed Response in Advanced Non-small Cell Lung CancerDavid E Gerber, Yating Wang, Suresh S Ramalingam, et al.
Clinical Lung Cancer|September 7, 2021
CheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent Chemoradiotherapy Followed by Nivolumab With or Without Ipilimumab Versus Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, Locally Advanced Stage III Non-Small-Cell Lung CancerDirk De Ruysscher, Suresh Ramalingam, James Urbanic, et al.
Pageof 29